EP3330276A1 — Novel bicyclic nucleosides and oligomers prepared therefrom
Assigned to Universitaet Bern · Expires 2018-06-06 · 8y expired
What this patent protects
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I) wherein one of T 1 and T 2 is OR , or OR 2 ; and the other of T 1 and T 2 is OR 1 or OR 2 ; wherein …
USPTO Abstract
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I) wherein one of T 1 and T 2 is OR , or OR 2 ; and the other of T 1 and T 2 is OR 1 or OR 2 ; wherein R 1 is H or a hydroxyl protecting group, and R 2 is a phosphorus moiety; and wherein Bx is a nucleobase. Furthermore, the present invention relates to said compounds, bicyclic nucleosides and said oligomers for use as a medicament in the prevention, treatment or diagnosis of a disease.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.